在没有糖尿病的患者急性心肌梗塞后,甲福明对左心室功能的影响:GIPS-III随机临床试验
Chris P H Lexis1, Iwan C C van der Horst2, Erik Lipsic1
1University of Groningen, University Medical Center Groningen, Department of Cardiology, Groningen, the Netherlands.
JAMA
|April 2, 2014
概括
在没有糖尿病的患者中,甲胺在心脏病发作后没有改善左心室喷射率. 这项研究表明,在这个患者群体中,甲福明对保持心脏功能没有好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 众所周知,甲福明可以改善心肌梗塞后糖尿病患者的治疗结果.
- 动物研究表明,甲福明可以保持左心室功能.
研究的目的:
- 评估甲福明对ST段升高心肌梗塞 (STEMI) 的非糖尿病患者左心室功能的影响.
主要方法:
- 这是一项双盲,安慰剂控制的研究,涉及380名接受STEMI初级皮肤冠状动脉干预 (PCI) 的患者.
- 患者在4个月内接受甲福明 (每天两次500毫克) 或安慰剂.
- 在4个月后通过MRI评估左心室喷射分数 (LVEF).
主要成果:
- 在4个月后,在甲福明和安慰剂组之间没有观察到LVEF的显著差异 (53.1%对54.8%,P=10).
- 二次测量,包括NT-proBNP水平和主要心脏不良事件 (MACE),也没有显著差异.
- 没有报告乳酸性化病例,功能和糖化血红蛋白水平在各组之间保持相似.
结论:
- 在接受初级PCI的非糖尿病STEMI患者中,甲福明治疗没有改善LVEF.
- 这些发现不支持在这种特定患者群体中使用甲福明来保护左心室功能.
相关概念视频
Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Angina IV: Management
493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343


